Dr. Conti is currently an Associate Professor of Markets, Public Policy and Law in the Questrom School of Business at Boston University. She currently co-directs the Technology Policy and Research Institute at Boston University’s Questrom School of Business and School of Law. Between 2006 and 2018, she was on the faculty at the University of Chicago.

She has conducted research on a wide variety of health economics and policy topics, and most of her work focuses on the economics and regulation of biotechnology, including prescription drugs. Specific topics on which she has completed research and published empirical work include the on[1]and off-label usage of, and associated spending on, prescription drugs and the financial and nonfinancial determinants of physician prescribing behaviors. She has written extensively on the pricing of brand pharmaceutical products and its determinants. She also studies prescription drugs undergoing patent expiration and generic entry and the resulting empirical effects on prices and use.

Dr. Conti has testified before the U.S. Senate Finance Committee regarding the economic causes of ongoing drug shortages, the U.S. House of Representative’s Oversight Committee on Competition in prescription drug markets, and the Senate Finance Committee on the high prices of prescription drugs. She also served as a special government expert to the U.S. Food and Drug Administration (FDA) and the Center for Medicare and Medicaid Services (CMS).

Ph.D., Health Policy (Economics Track), Harvard University; B.A., Philosophy (History minor), Kenyon
College.

Main Line: 617.871.6900
Facsimile: 617.871.6949